Howard C. Birndorf - 14 Nov 2022 Form 4 Insider Report for Adamis Pharmaceuticals Corp

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 14 Nov 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Nov 2022, 15:41:21 UTC
Source filing: View source filing
Reporting owner signature: /s/ David J. Marguglio, as attorney-in-fact for Howard C. Birndorf

Key filing fact

Howard C. Birndorf filed Form 4 for Adamis Pharmaceuticals Corp on 16 Nov 2022.

Key facts

This page summarizes Howard C. Birndorf's Form 4 filing for Adamis Pharmaceuticals Corp.
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 16 Nov 2022, 15:41.

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ADMP transaction Derivative

Disposed to Issuer

ADMP transaction Derivative

Award

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Explanation of responses 1 footnote

Footnote F1

The two reported transactions involved an amendment to extend the term of an outstanding investor warrant originally issued on November 15, 2007.